Russell Michael G N, Carling Robert W, Atack John R, Bromidge Frances A, Cook Susan M, Hunt Peter, Isted Catherine, Lucas Matt, McKernan Ruth M, Mitchinson Andrew, Moore Kevin W, Narquizian Robert, Macaulay Alison J, Thomas David, Thompson Sally-Anne, Wafford Keith A, Castro José L
Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, U.K.
J Med Chem. 2005 Mar 10;48(5):1367-83. doi: 10.1021/jm040883v.
We have previously identified the 7,8,9,10-tetrahydro-7,10-ethano-1,2,4-triazolo[3,4-a]phthalazine (1) as a potent partial agonist for the alpha(3) receptor subtype with 5-fold selectivity in binding affinity over alpha(1). This paper describes a detailed investigation of the substituents on this core structure at both the 3- and 6-positions. Despite evaluating a wide range of groups, the maximum selectivity that could be achieved in terms of affinity for the alpha(3) subtype over the alpha(1) subtype was 12-fold (for 57). Although most analogues showed no selectivity in terms of efficacy, some did show partial agonism at alpha(1) and antagonism at alpha(3) (e.g., 25 and 75). However, two analogues tested (93 and 96), both with triazole substituents in the 6-position, showed significantly higher efficacy for the alpha(3) subtype over the alpha(1) subtype. This was the first indication that selectivity in efficacy in the required direction could be achieved in this series.
我们之前已鉴定出7,8,9,10 - 四氢 - 7,10 - 亚乙基 - 1,2,4 - 三唑并[3,4 - a]酞嗪(1)是α(3)受体亚型的强效部分激动剂,其结合亲和力对α(1)具有5倍选择性。本文描述了对该核心结构3位和6位取代基的详细研究。尽管评估了广泛的基团,但就对α(3)亚型的亲和力相对于α(1)亚型而言,能够实现的最大选择性为12倍(对于57)。尽管大多数类似物在效力方面没有显示出选择性,但有些确实在α(1)处显示出部分激动作用,而在α(3)处显示出拮抗作用(例如25和75)。然而,测试的两个类似物(93和96),在6位均带有三唑取代基,显示出对α(3)亚型的效力明显高于α(1)亚型。这是该系列中能够在所需方向上实现效力选择性的首个迹象。